The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset

British Journal of Pharmacology

Volumn 124, Issue 2, 1998, Pages 409-415

  Harries, M H ^a   Samson, N A ^a   Cilia, J ^a   Hunter, A J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Blood pressure; Emesis; Learning and memory; M1 partial agonist; Sabcomeline

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; MUSCARINIC M1 RECEPTOR AGONIST; PARTIAL AGONIST; SABCOMELINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; COGNITION; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; LEARNING; MALE; MARMOSET; NONHUMAN; PRIORITY JOURNAL; VISUAL DISCRIMINATION; VOMITING;

ALZHEIMER DISEASE; ANIMALS; BLOOD PRESSURE; CALLITHRIX; FEMALE; IMINES; LEARNING; MALE; MEMORY; MUSCARINIC AGONISTS; PARASYMPATHOMIMETICS; PATTERN RECOGNITION, VISUAL; QUINUCLIDINES; RECEPTOR, MUSCARINIC M1; RECEPTORS, MUSCARINIC; SUCCINIMIDES;

EID: 0031863602     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701844     Document Type: Article

References (34)

1. ALLISON, R.S. & HURWITZ, L.J. (1967). On perseveration in aphasics. Brain, 90, 429-448.
2. BARNES, J.C. & ROBERTS, F.F. (1991). Central effects of muscarinic agonists and antagonists on hippocampal theta rhythm and blood pressure in the anaesthetised rat. Eur. J. Pharmacol., 195, 233-240.
3. BARTUS, R.T. & JOHNSON, H.R. (1976). Short-term memory in the rhesus monkey: disruption from the anticholinergic scopolamine. Pharmacol. Biochem. Behav., 5, 39-46.
4. BAYLES, K.A., TOMOEDA, C.K., KASZNIAK, A.W., STERN, L.Z. & EAGANS, K.K. (1985). Verbal perseveration of dementia patients. Brain Lang., 25, 102-116.
5. BROMIDGE, S.M., CASSIDY, F., CLARK, M.S.G., EGGLESTON, D.S. & ORLEK, B.S. (1994). Synthesis and properties of [R-(Z)]-(+)-α-(1-azabicyclo [2.2.2] oct-3-y1)-α-(methoxyimino) acetonitrile, a novel functionally selective muscarinic partial agonist. J. Chem. Soc. Chem. Commun., 18, 2189-2190.
6. CEREDA, E., BRAMBILLA, A, EZHAYA, A., GAIDA, W., MEDLA, K., MONFERINI, E., PITSIKAS, N., SCHIAVI, G.B. & SAGRADA, A. (1994). Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders. Eur. J. Drug Metab. Pharmacokinet., 19, 179-183.
7. CLAGUE, R.U., EGLEN, R.M., STRACHAN, A.C. & WHITING, R.L. (1985). Action of agonists and antagonists at muscarinic receptors present on ileum and atria in vitro. Br. J. Pharmacol., 86, 163-170.
8. 1-receptor agonists: potential in the treatment of Alzheimer's disease. CNS Drugs, 3, 467-481.
9. EGLEN, R.M. & WATSON, N. (1996). Selective muscarinic receptor agonists and antagonists. Pharmacol. Toxicol., 78, 59-68.
10. FISHER, A. & BARAK, D. (1994). Progress and persepectives in new muscarinic agonists. Drug News Perspect., 7, 453-464.
11. 1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Ann. New York Acad. Sci., 777, 189-196.
12. FREEMAN, T. & GATHERCOLE, C.E. (1966). Perseveration - the clinical symptoms - in chronic schizophrenic and organic dementia. Br. J. Psychiatry. 112, 27-32.
13. HAROUTUNIAN, V., BARNES, E. & DAVIS, K.L. (1985). Cholinergic modulation of memory in rats. Psychopharmacology. 87, 266-271.
14. KUMAR, R., CEDAR, E., CLARK, M.S.G., LOUDON, J.M. & MCCAFFERTY, J.P.C. (1996). Muscarinic partial agonists in the symptomatic treatment of Alzheimer's disease. In Alzheimer Disease: From Molecular Biology to Therapy, ed. Becker R. & Giacobini E. pp. 299-303, Boston: Birkhauser.
15. LEHERICY, S., HIRSCH, E.C., CERVERA-PIEROT, P., HERSH, L.B., BAKCHINE, S., PIETTE, F., DUYCKAERTS, C., HAUW, J-J., JAVOY-AGID, F. & AGID, Y. (1993). Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J. Comp. Neurol., 330, 15-31.
16. 1 receptors. J. Pharmacol. Exp. Ther., 283, 1059-1068.
17. 1 partial agonist, enhances cognition at doses which do not induce side effects. Neurobiol. Aging, 17, S30.
18. MEDINA, A., BODICK, N., GOLDBERGER, A.L., MACMAHON, M. & LIPSITZ, L.A. (1997). Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Hypertension, 29, 828-834.
19. M'HARZI, M., PALOU, A.M., OBERLANDER, C. & BARZAGHI. F. (1995). Antagonism of scopolamine-induced memory impairments in rats by the muscarinic agonist RU 35, 926 (CI-979). Pharmacol. Biochem. Behav., 51, 119-124.
20. 1 agonist AF102B. Jpn. J. Pharmacol., 48, 502-506.
21. OHTANI, Y., MURASAKI, M., ISHII, Y., ISHIGOOKA, J. & MUIRA, S. (1990). Phase I study of FKS-508 single and multiple dose studies. Eur. J. Pharmacol., 183, 1038.
22. RAFFAELE, K.C., ASTHANA, S., BERARDI, A., HAXBY, J.V., MORRIS, P.P., SCHAPIRO, M.B. & SONCRANT, T.T. (1996). Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease. Neuropsychopharmacology, 15, 163-170.
23. RAFFAELE, K.C., BERARDI, A., ASTHANA, S., MORRIS, P., HAXBY, J.V. & SONCRANT, T.T. (1991a). Effects of long term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type. Psychopharmacol. Bull., 27, 315-319.
24. RAFFAELE, K.C., BERARDI, A., MORRIS, P.P., ASTHANA, S., HAXBY, J.V., SCHAPIRO, M.B., RAPOPORT, S.I. & SONCRANT, T.T. (1991b). Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type. Prog. Neuropsychopharmacol. Biol. Psychiatry, 15, 643-648.
25. RIDLEY, R.M., BARRATT, N.G. & BAKER, H.F. (1984). Cholinergic learning deficits in the marmoset produced by scopolamine and I.C.V. hemicholinium. Psychopharmacology, 83, 340-345.
26. ROBERTS, A.C., ROBBINS, T.W., EVERITT, B.J., JONES, G.H., SIRKIA, T.E., WILKINSON, J. & PAGE, K. (1990). The effects of excitotoxic lesions of the basal forebrain on the acquisition, retention and serial reversal of visual discriminations in marmosets. Neuroscience, 34, 311-329.
27. RUPNIAK, N.M.J., TYE, S.J. & IVERSEN, S.D. (1992). Comparison of the effects of selective and nonselective muscarinic agonists on cognition and thermoregulation in primates. J. Neurol. Sci., 110, 222-227.
28. 3 muscarinic agonist activity in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 19, 85-91.
29. SRAMEK, J.J., SEDMAN, A.J., REECE, P.A., HOURANI, J., BOCKBRADER, H. & CUTLER, N.R. (1995b). Safety and tolerability of Cl-979 in patients with Alzheimer's disease. Life Sci., 57, 503-510.
30. SUZUKI, M., YAMAGUCHI, T., OZAWA, Y., IWAI, A & YAMAMOTO, M. (1995). Effects of YM796, a novel muscarinic agonist, on the impairment of passive avoidance response in senescence-accelerated mice. Pharmacol. Biochem. Behav., 51, 623-626.
31. UKAI, M., SHINKAI, N. & KAMEYAMA, T. (1995). Cholinergic receptor agonists inhibit pirenzipine-induced dysfunction of spontaneous alternation performance in the mouse. Gen. Pharmacol., 26, 1529-1532.
32. WETTSTEIN, A. & SPIEGEL, R. (1984). Clinical trials with the cholinergic drug RS86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology, 84, 572-573.
33. WHITEHOUSE, P.J., PRICE, D.L., STRUBLE, R.G., CLARK, A.W., COYLE, J.T. & DELONG, M.R. (1982). Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science, 215, 1237-1239.
34. WILFFERT, B., DAVIDESKO, D., DE JONGE, A., THOOLEN, M.J.M.C., TIMMERMANS, P.B.M.W.M. & VAN ZWEITEN, P.A. (1983). Role of ganglionic M-1 and M-2 receptors in the neuronal control of the cardiovascular system of the normotensive rats as determined with pilocarpine. Eur. J. Pharmacol., 95, 109-116.